Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry -- haven't been checking in lately.
I don't know that IR firm...is it a PR service instead? They don't appear to have any NIRI credentials - which is a baseline quality check for IR nowadays. Usually IR firms of note list their staff and strategies...I'm not saying IRP was any big shakes but the senior partner had good training at FRB back in the day.
Someone else pointed me to an IR firm which looks like someone who is a flat-fee writer. He could be fine..but if someone is writing for a flat fee - it brings up the question of whether they are able (or willing) to look at an investor presentation critically -- or if they simply do what management wants to say.
As far as AHAR...I may have crossed my wires. It is owned not by Vincent Ahonkhai, whose ties to the Gates Foundation I've had difficulty fact checking. AHAR, however, has had ties to IMUN for years and GB Global. It's key physician seems to operate primarily out of NJ and under several different practices. AHAR also did the bridging study for IMUN. If we go back 3-5 years - deals with GB Global and AHAR went nowhere....so I am simply saying the second time may not be the charm. Why would AHAR pay such an inflated price for LDN relative to other orders? Do they expect to pass it through to patients or does it help boost IMUN's margins....I don't really want to dig into related company transactions -- and while there may not be any in the filings -- I think there are.
This company completely changed its business plan from one it sort of knew something about to one where its business strategy is essentially every hot stock trend in the book.
Looks like you may be proven correct.
They've been using that exact same cobbled together deck for at least two years now -- possibly longer....so most of it is out of date...or perhaps - misleading. I don't know if their new IR person will deal with it -- but it has never been a priority for management.
Pretty sure NG is writing the PRs (although the attorney may be reviewing them)...she has a very distinct writing style based on drafts I've seen over the years.
And note that any transaction with AHAR is pretty far from an arm's length transaction -- and it's not simply because AHAR did the bridging trial.
Auguster --
In my experience (I've done IR and research for years) it does. However, some managements are difficult to coach.. and some IR types want to cookie-cutter their corporate clients into a house standard strategy.
Well -- IMUN isn't working with their IR firm of the past year or so.
The phone number on the PR is the main number at IMUN and it tells you to call their old IR firm IRP....so good luck with that.
Call me cynical - but they shipped -- they didn't say they got paid for it....big difference.
Pretty sure you won't be getting anything anytime soon based on conversation I had last week with someone who used to work with them.
What number did you call -- you can PM me if you don't want to post publicly. It may be the personal phone number for the current/former? IR guy. I can't send PMs but can respond to you via email.
Yes there are a lot of issues...as you point out approvals in Africa take time -- and the process is not always a straight line -- as we saw with Nigeria, things should have been done a year ago when there was a GMP inspection in the DR....I remember NG and others saying it was the last step...but once they got through what they thought was the final hoop...another one appeared.
Personally, I've found it difficult to verify much of what is put into their PRs...if you google large sections you will find they link to some random quote about HIV and Africa - particularly when it comes to infection rates. I recall one in particular where NG used an estimate - but I pointed out to her that she was extrapolating off a small sample study by an NGO....the way she wrote it - it all sounded too good to be true -- when one checked the numbers -- it was.
There also seems a tendency to attach high-profile institutions/names to their activities as if those institutions explicitly endorse IMUN or LDN. One that springs to mind is a conference on HIV in Africa that was characterized as being affiliated with Harvard Medical school -- a little digging and it seemed more like the conference organizers rented an event space at Harvard - but the school appears to have been in no other way affiliated with the event.
The holders (including key investors) are often way under water in this stock -- it strikes me that nothing is actually happening in the business and they are simply putting the most positive face forward.
la_ltrader - I can't send PMs but I can receive. Send me your contact info and I may have some observations to share off board.
i guess my question is why they need a new wire service. those aren't complex negotiations. Do you mean they needed new IR representation - because that is a different matter.
My guess is that it is a Chinese company that recently moved its headquarters to the US. Shouldn't be too hard to figure out.
Based entirely on personal experience. They are all very enthusiastic....particularly on the investor side...but what else can they do?
I am curious who their new IR firm will be - if that change is actually happening. My guess is someone tied to the group that took over Silberstein's investment...so maybe someone out of Chicago.
Unless they completely cleaned house of management and board members, I think you are sorely mistaken about caliber.
Interesting that a firm specializing in international debt collections is involved. Guess that must be all the rumored bad China deals.
They needed a local "bridging trial" to get acceptance in Nigeria. That is required in a lot of countries where there is a significantly different population than that the drug was originally tested on. Japan requires bridging trials for all drugs as a rule.
A bridging trial can help support application to the FDA but it is by no means a substitute for a phase III trial.
How does FDA approval affect sales in Africa? Because NGOs are more likely to buy a product if it is FDA approved?
Naltrexone has been FDA approved for years.
However, I don't see IMUN getting to a point where they can even begin to afford a phase III trial in the US....for even one indication - let alone every indication they company believes it treats.
The only thing one can say about LDN is that it is unlikely to harm a patient.
That is not the correct website. Did you actually look at it?
I'm pretty certain it's still IRP running the investor relations effort. But who knows, maybe the problems at ATLT caused ADTM to distance itself from IRP.
How many "hot stock" buzzwords can one put in a single PR?
Still doesn't breed a tremendous amount of confidence.
Well - website failed to go live. one promise broken. there will be many more.
IRP is otherwise occupied.
Survey says "ding"
Interesting. I've heard rumblings that MYDX got involved in some bad deals in Asia - that had little to nothing to do with MYDX business. Perhaps there was some commingling of business and personal interests.
ADTM --- wouldn't touch it with someone else's 10 foot pole. Same people involved with ATLT....and GRNH and MYDX.....
Personally, I don't recommend touching anything where there are any ties to an SEC investigation -- no matter how distant. Investors got played in this ridiculous "takeover" - now this company wants to do cannabis...maybe because the key investors want out of the business. Maybe they will try to merge with GRNH this time around.
Look at the list of principals. You'll probably have to put a couple of documents together.
Yes - you are correct on that. And Lynx is essentially their investor relations firm....or person. Money laundering and/or tax evasion seem like reasonable suspicions...especially with the company's increasingly bizarre corporate structure. There is no reason to have some of the subsidiaries they have.
I haven't found any past allegations associated with Arc Capital on laundering - have you?
Is there a specific mention of Lynx? I know it is on the list of holders/vendors.
Here's my bet. ATLT gets some absurd tender offer from a company out of nowhere.....ATLT will be the surviving entity.....merger never happens.....shareholders vote out management.....sell assets and recycle the shell.
See ADTM.
Agreed. There's a lot more to this than simply ATLT. And these people do their homework....maybe it isn't evident when one speaks to a paralegal (contacts on the sheet)...but it strikes me that parties involved in this stock have raised concerns for awhile.
It ain't just Lynx. The Arc Capital guys have been under investigation/convicted before.
It's cockroach theory.
I don't believe I posted any comments on the quarters for ATLT. Possibly that the original guidance for June (?) quarter was pretty modest - but they beat that. They issue guidance before they do a hard close for the quarter - so there are estimates involved - along with what the auditors would allow under revenue recognition guidelines.
People follow stocks for lots of reasons - not just because they are invested in a stock or sector....could be simply that I know someone who works there as an example.
It's March 2017....so quite literally 2 quarters ago....
I'm a researcher (WSJ/II awarded analyst) and do work for other people. No interest in owning this - not a bad business model (although I think the whole licensing thing is just a way of driving the price up on higher margins - without mentioning that the revenues will likely be a lot lower)...just too many people as advisors who like to color outside the lines so to speak.
I have to figure out the original source -- it may have been a shareholder letter early this year.
That said it is clearly in the About Us section of the Company's website.
Founded in 2016, Atlas Technology (ATLT-OECQB) designs and sells touchscreens to companies such as Gevalia and Kyocera. Its executives have over 30 years combined experience in touchscreen technology. Importantly, Atlas outsources all of its manufacturing, enabling it to focus on developing new technologies and intellectual property while taking advantage of the manufacturing capacity surplus. As a result, Atlas Technology offers its customers the best combination of design, technology and value.
Here -- March Quarter EPS results. Atlas Technology International Exceeds Guidance in Third Fiscal Quarter Results – Record Revenues and Earnings
Revenues Rise 81% Sequentially From Second Fiscal Quarter
May 15, 2017
http://irdirect.net/ATLT/press_releases
It's a sales showroom. They will have several products like the Honeywell thermostat on display...and maybe some of the coffee machines. They share office space with their IR firm. Or rather the IR firm shares office space with ATLT.
A glut in screen production capacity is cited in all of their filings. They benefit from this because they can bid low for idle production space. If that glut goes away, production costs will go up. Although it doesn't mean that pricing for ATLT's products won't go up as well.
Re: orders: They are starting from zilch - and because they have relatively small order size - they are able to work into production lines that have amounts of downtime that won't suit a larger order/customer. They sell most of their products to assemblers (like Honeywell) for $0.50-$3 on the high end.